Cardiac Safety Services Market

Cardiac Safety Services Market by Type (Standalone, Integrated), Services (ECG/Holter measurement, Blood Pressure measurement, Cardiac Imaging, Thorough QT Studies), End User (Pharmaceutical, Biopharma, CROs), Region - Global Forecasts to 2027

Report Code: PH 7455 Aug, 2022, by marketsandmarkets.com

The global cardiac safety services market size is projected to reach USD 1.0 billion by 2027, at a CAGR of 11.2% during the forecast period. The growing R&D expenditure in the pharmaceutical & biopharmaceutical industry coupled with surge in outsourcing of R&D activities are the key factors driving the growth of this market.

Cardiac Safety Services Market

To know about the assumptions considered for the study, Request for Free Sample Report

Cardiac Safety Services Market Global Dynamics

Drivers: Rising R&D expenditure in pharmaceutical & biopharmaceutical industry

Pharmaceutical companies invest in R&D to deliver high-quality and innovative products in the market. Current trends suggest that top pharmaceutical companies are increasing their R&D efficiencies through heavy R&D investments to see returns on their investment in the longer term and through collaborative R&D efforts. This will contribute to the increased demand for preclinical and clinical services including cardiac safety evaluation.

Opportunities: Growth in biosimilars and biologics markets

Many companies are investing heavily in the development of biologics and biosimilar molecules. More than half of the drug candidates in the discovery stage are biologics, such as proteins, peptides, and monoclonal antibodies. As newer biologics are being discovered or are in the pipeline, pharmaceutical and biopharmaceutical companies are heavily investing in their R&D. Further, biosimilars are cost-effective because they are not required to comply with stringent regulatory requirements, as they are generic versions of patented biologic drugs. Thus, compared to small molecules, biologics and biosimilars require specialized testing services. This will bring opportunities for safety assessment providers to expand their portfolios and capabilities

Restraints: High cost of cardiac safety services

The rising costs of drug development and the decline in the number of new drugs approved in the US are significant problems that threaten public health. Cardiac safety evaluations of off-target drug effects are generally expensive, time-consuming, and contribute to the termination of many new molecular entities. This affects the demand for cardiac safety evaluation studies and hinders overall drug development.

The Integrated services segment is expected to have the dominant share of the market by type in 2021:

Integrated services are provided as a bundle of services to pharmaceutical and biopharmaceutical companies. These state-of-the-art core lab services offer an end-to-end suite of cardiac safety services, such as imaging services, TQT studies, and profile QT studies. They also monitor off-target cardiovascular liability and onsite multichannel telemetry conducted by certified nurses to aid in the real-time assessment of heart rate and rhythm. As a result, these services help enhance and expedite clinical trials in the pharmaceutical and biopharmaceutical development cycle.

Cardiac Safety Services Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America was the largest regional market for cardiac safety services market in 2021.

The market is segmented into major regions—North America, Europe, the Asia Pacific, Rest of World. North America is a mature market for cardiac safety services and is estimated to grow at a highest CAGR during the forecast period. This can be attributed to the increasing number of clinical trials in the region that are driving the demand for cardiac safety services.

Cardiac Safety Services Market Key Players

Key players in the market include Laboratory Corporation of America Holdings (US), Koninklijke Philips N.V. (Netherlands), Clario (US), Banook Group (France), IQVIA (US), Biotrial (France), Certara (US), Celerion (US), Medpace (US), Ncardia (Netherlands), Richmond Pharmacology (UK), PhysioStim (France), Shanghai Medicilon (China), Pharmaceutical Product Development (US), and SGS (Switzerland).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2020–2027

Base year considered

2021

Forecast period

2022–2027

Forecast units

Value (USD)

Segments covered

Type, Type of Services, End User and Region

Geographies covered

North America, Europe, Asia Pacific, and Rest of the World

Companies covered

Laboratory Corporation of America Holdings (US), Koninklijke Philips N.V. (Netherlands), Clario (US), Banook Group (France), IQVIA (US), Biotrial (France), Certara (US), Celerion (US), Medpace (US), Ncardia (Netherlands), Richmond Pharmacology (UK), PhysioStim (France), Shanghai Medicilon (China), Pharmaceutical Product Development (US), and SGS (Switzerland)

This report categorizes the global cardiac safety services market into the following segments and subsegments

By Type

  • Integrated Services
  • Standalone Services

By Type of Service

  • ECG/Holter Measurement
  • Blood Pressure Measurement
  • Cardiovascular Imaging
  • Thorough QT Studies
  • Other Services

By End User

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • RoE
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Rest of the World

Recent Developments

  • In February 2021, Koninklijke Philips N.V. (Netherlands) acquired Biotelemetry (US). This acquisition enhanced the company’s cardiac care portfolio and transformed care delivery along the health continuum with integrated solutions.
  • In March 2019, BioTelemetry acquired Geneva Healthcare, Inc., a leading provider of remote monitoring for implantable cardiac devices.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 20)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION
    1.3 STUDY SCOPE
          FIGURE 1 CARDIAC SAFETY SERVICES MARKET
    1.4 YEARS CONSIDERED
    1.5 CURRENCY CONSIDERED
    1.6 LIMITATIONS
    1.7 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. - 23)

    2.1 RESEARCH DATA
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
           2.2.1 BOTTOM-UP APPROACH
                    FIGURE 4 BOTTOM-UP APPROACH
           2.2.2 TOP-DOWN APPROACH
                    FIGURE 5 TOP-DOWN APPROACH
           2.2.3 GROWTH FORECAST
    2.3 DATA TRIANGULATION
          FIGURE 6 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY (Page No. - 31)
    FIGURE 7 CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2022 VS. 2027 (USD MILLION)
    FIGURE 8 CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 9 CARDIAC SAFETY SERVICES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 10 GEOGRAPHICAL SNAPSHOT OF CARDIAC SAFETY SERVICES MARKET

4 PREMIUM INSIGHTS (Page No. - 34)
    4.1 CARDIAC SAFETY SERVICES MARKET OVERVIEW
          FIGURE 11 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET SHARE, BY TYPE AND COUNTRY (2021)
          FIGURE 12 INTEGRATED SERVICES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021
    4.3 CARDIAC SAFETY SERVICES MARKET SHARE, BY TYPE OF SERVICE, 2022 VS. 2027
          FIGURE 13 ECG/HOLTER MEASUREMENT SERVICES SEGMENT TO DOMINATE MARKET IN 2027
    4.4 CARDIAC SAFETY SERVICES MARKET SHARE, BY END USER, 2022
          FIGURE 14 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2022
    4.5 CARDIAC SAFETY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
          FIGURE 15 EUROPEAN COUNTRIES TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 38)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
          FIGURE 16 CARDIAC SAFETY SERVICES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Growing R&D expenditure in pharmaceutical & biopharmaceutical industry
                                FIGURE 17 GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026
                    5.2.1.2 Increased outsourcing of R&D activities
                                FIGURE 18 ACTIVE PHARMACEUTICAL DRUG PIPELINE, JANUARY 2011 TO JANUARY 2021
                    5.2.1.3 Increasing number of clinical trials
                                FIGURE 19 INCREASING NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2021)
           5.2.2 OPPORTUNITIES
                    5.2.2.1 Introduction of new technologies and methods
                    5.2.2.2 Growth in biosimilars and biologics markets
           5.2.3 CHALLENGES
                    5.2.3.1 High cost of cardiac safety evaluation

6 CARDIAC SAFETY SERVICES MARKET, BY TYPE (Page No. - 43)
    6.1 INTRODUCTION
          TABLE 1 CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
    6.2 INTEGRATED SERVICES
           6.2.1 INTEGRATED SERVICES TO DOMINATE CARDIAC SAFETY SERVICES MARKET
                    TABLE 2 INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 3 NORTH AMERICA: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 4 EUROPE: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 5 ASIA PACIFIC: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 STANDALONE SERVICES
           6.3.1 STANDALONE SERVICES SEGMENT WITNESSING GROWTH DUE TO COST-EFFECTIVENESS
                    TABLE 6 STANDALONE CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 7 NORTH AMERICA: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 8 EUROPE: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 9 ASIA PACIFIC: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7 CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE (Page No. - 49)
    7.1 INTRODUCTION
          TABLE 10 CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
    7.2 ECG/HOLTER MEASUREMENT SERVICES
           7.2.1 ECG/HOLTER MEASUREMENT SERVICES SUPPORT R&D IN NOVEL METHODS FOR CLINICAL TRIALS AND DRUG DISCOVERY
                    TABLE 11 ECG/HOLTER MEASUREMENT SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 12 NORTH AMERICA: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 13 EUROPE: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 14 ASIA PACIFIC: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 BLOOD PRESSURE MEASUREMENT SERVICES
           7.3.1 INCREASING R&D ACTIVITIES TO DRIVE MARKET GROWTH
                    TABLE 15 BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 16 NORTH AMERICA: BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 17 EUROPE: BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 18 ASIA PACIFIC: BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    7.4 CARDIOVASCULAR IMAGING SERVICES
           7.4.1 CARDIOVASCULAR IMAGING SERVICES HELP IN DRUG EVALUATION
                    TABLE 19 CARDIOVASCULAR IMAGING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 20 NORTH AMERICA: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 21 EUROPE: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 22 ASIA PACIFIC: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    7.5 THOROUGH QT STUDIES
           7.5.1 NEED TO MEET STRINGENT REGULATORY REQUIREMENTS TO DRIVE DEMAND FOR THOROUGH QT STUDIES
                    TABLE 23 THOROUGH QT STUDIES MARKET, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 24 NORTH AMERICA: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 25 EUROPE: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 26 ASIA PACIFIC: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    7.6 OTHER SERVICES
          TABLE 27 OTHER CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
          TABLE 28 NORTH AMERICA: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 29 EUROPE: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 30 ASIA PACIFIC: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

8 CARDIAC SAFETY SERVICES MARKET, BY END USER (Page No. - 60)
    8.1 INTRODUCTION
          TABLE 31 CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
    8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
           8.2.1 INCREASING R&D BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE DEMAND FOR CARDIAC SAFETY SERVICES
                    TABLE 32 CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 33 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 34 EUROPE: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 35 ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 CONTRACT RESEARCH ORGANIZATIONS
           8.3.1 INCREASING OUTSOURCING OF DRUG DISCOVERY PROCESSES TO SUPPORT SEGMENT GROWTH
                    TABLE 36 CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION)
                    TABLE 37 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 38 EUROPE: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
                    TABLE 39 ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)

9 CARDIAC SAFETY SERVICES MARKET, BY REGION (Page No. - 66)
    9.1 INTRODUCTION
          TABLE 40 CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
    9.2 NORTH AMERICA
          FIGURE 20 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET SNAPSHOT
          TABLE 41 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 42 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
          TABLE 43 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 44 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.2.1 US
                    9.2.1.1 US dominates global cardiac safety services market
                                TABLE 45 US: TOTAL NUMBER OF CLINICAL TRIALS (2019)
                                TABLE 46 US: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
                                TABLE 47 US: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 48 US: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Canada has high-quality clinical trial infrastructure and expertise
                                TABLE 49 CANADA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
                                TABLE 50 CANADA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 51 CANADA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.3 EUROPE
          FIGURE 21 EUROPE: CARDIAC SAFETY SERVICES MARKET SNAPSHOT
          TABLE 52 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 53 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
          TABLE 54 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 55 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Availability of skilled staff and flexible labor laws have made Germany a popular EU hub for clinical trials
                                TABLE 56 GERMANY: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
                                TABLE 57 GERMANY: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 58 GERMANY: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.2 UK
                    9.3.2.1 Steady growth of pharmaceutical R&D expenditure indicates favorable prospects for cardiac safety services
                                TABLE 59 UK: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
                                TABLE 60 UK: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 61 UK: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.3 FRANCE
                    9.3.3.1 High clinical trial activity for cancer therapies to drive market growth
                                TABLE 62 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
                                TABLE 63 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 64 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Strong pharma industry and availability of funding for drug development fuel market growth
                                TABLE 65 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021)
                                TABLE 66 ITALY: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
                                TABLE 67 ITALY: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 68 ITALY: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Growing investment in pharmaceutical R&D and a favorable climate for approvals boost market growth
                                TABLE 69 SPAIN: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
                                TABLE 70 SPAIN: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 71 SPAIN: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.3.6 REST OF EUROPE
                    TABLE 72 ROE: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
                    TABLE 73 ROE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 74 ROE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.4 ASIA PACIFIC
          TABLE 75 APAC: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
          TABLE 76 APAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
          TABLE 77 APAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 78 APAC: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 China dominates APAC market for cardiac safety services
                                TABLE 79 CHINA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
                                TABLE 80 CHINA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 81 CHINA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Strong IP rights and supportive policies have strengthened R&D sector in Japan
                                TABLE 82 JAPAN: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
                                TABLE 83 JAPAN: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 84 JAPAN: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Lack of language barriers and availability of trained resources make India an attractive destination for clinical trials
                                TABLE 85 INDIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
                                TABLE 86 INDIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 87 INDIA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.4 AUSTRALIA
                    9.4.4.1 Favorable R&D tax incentives and cash rebates have driven clinical trial activity in Australia
                                TABLE 88 AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
                                TABLE 89 AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                TABLE 90 AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
           9.4.5 REST OF ASIA PACIFIC
                    TABLE 91 ROAPAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
                    TABLE 92 ROAPAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
                    TABLE 93 ROAPAC: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.5 REST OF THE WORLD
          TABLE 94 ROW: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
          TABLE 95 ROW: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 96 ROW: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 97)
     10.1 OVERVIEW
             FIGURE 22 KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2019–2022
     10.2 MARKET PLAYER RANKING
             TABLE 97 GLOBAL CARDIAC SAFETY SERVICES MARKET PLAYER RANKING, 2021
     10.3 COMPETITIVE LEADERSHIP MAPPING
             10.3.1 VISIONARY LEADERS
             10.3.2 DYNAMIC DIFFERENTIATORS
             10.3.3 INNOVATORS
             10.3.4 EMERGING COMPANIES
                        FIGURE 23 CARDIAC SAFETY SERVICES MARKET: COMPETITIVE LEADERSHIP MAPPING
     10.4 COMPETITIVE SITUATION AND TRENDS
             10.4.1 ACQUISITIONS
                        TABLE 98 ACQUISITIONS, 2019–2022
             10.4.2 PARTNERSHIPS, ALLIANCES, AND AGREEMENTS
                        TABLE 99 PARTNERSHIPS, ALLIANCES, AND AGREEMENTS, 2019–2022
             10.4.3 EXPANSIONS
                        TABLE 100 EXPANSIONS, 2019–2022
             10.4.4 OTHER STRATEGIES
                        TABLE 101 OTHER STRATEGIES, 2019–2022

11 COMPANY PROFILES (Page No. - 103)
(Business overview, Products offered, Recent Developments, MNM view)*
     11.1 KEY PLAYERS
             11.1.1 LABORATORY CORPORATION OF AMERICA HOLDINGS
                        TABLE 102 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
                        FIGURE 24 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
             11.1.2 KONINKLIJKE PHILIPS
                        TABLE 103 KONINKLIJKE PHILIPS: BUSINESS OVERVIEW
                        FIGURE 25 KONINKLIJKE PHILIPS: COMPANY SNAPSHOT
             11.1.3 CLARIO
                        TABLE 104 CLARIO: BUSINESS OVERVIEW
             11.1.4 BANOOK GROUP
                        TABLE 105 BANOOK GROUP: BUSINESS OVERVIEW
             11.1.5 IQVIA
                        TABLE 106 IQVIA: BUSINESS OVERVIEW
                        FIGURE 26 IQVIA: COMPANY SNAPSHOT
             11.1.6 BIOTRIAL
                        TABLE 107 BIOTRIAL: BUSINESS OVERVIEW
             11.1.7 CERTARA
                        TABLE 108 CERTARA: BUSINESS OVERVIEW
                        FIGURE 27 CERTARA: COMPANY SNAPSHOT
             11.1.8 CELERION
                        TABLE 109 CELERION: BUSINESS OVERVIEW
             11.1.9 MEDPACE
                        TABLE 110 MEDPACE: BUSINESS OVERVIEW
                        FIGURE 28 MEDPACE: COMPANY SNAPSHOT
             11.1.10 NCARDIA
                        TABLE 111 NCARDIA: BUSINESS OVERVIEW
             11.1.11 RICHMOND PHARMACOLOGY
                        TABLE 112 RICHMOND PHARMACOLOGY: BUSINESS OVERVIEW
             11.1.12 PHYSIOSTIM
                        TABLE 113 PHYSIOSTIM: BUSINESS OVERVIEW
     11.2 OTHER PLAYERS
             11.2.1 SHANGHAI MEDICILON
             11.2.2 PHARMACEUTICAL PRODUCT DEVELOPMENT LLC.
             11.2.3 SGS S.A.

*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

12 APPENDIX (Page No. - 126)
     12.1 DISCUSSION GUIDE
     12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.3 CUSTOMIZATION OPTIONS
     12.4 RELATED REPORTS
     12.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the cardiac safety services market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the market. The secondary sources used for this study include Annual Reports, SEC Filings, Investor Presentations, World Health Organization (WHO), US Food and Drug Administration (FDA), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), Association of Clinical Research Organizations (ACRO), Clinical Research Society (CRS), Clinical Research Association of Canada (CRAC), Association of International Contract Research Organizations (AICROS), Clinical and Contract Research Association (CCRA), American Association of Pharmaceutical Scientists (AAPS), Pharmaceutical Research and Manufacturers of America (PhRMA), European Medicines Agency (EMA), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Safety Pharmacology Society (SPS), Cardiac Safety Research Consortium (CSRC). These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Cardiac Safety Services Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the cardiac safety services business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global cardiac safety services market based on the type, type of services, end user and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, challenges, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall cardiac safety services market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia Pacific, Rest of World
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the cardiac safety services market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • An additional five company profiles
Report Code
PH 7455
Published ON
Aug, 2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Cardiac Safety Services Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback